Harnessing the Innate Immune System to Target Cancer: A Novel Immunotherapeutic Strategy for Solid Tumours

利用先天免疫系统靶向癌症：实体瘤的新型免疫治疗策略

• 批准号: nhmrc : GNT1155938
• 负责人: A/Pr Trent Woodruff
• 金额: $ 65.13万
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/harnessing-innate-immune-solid-tumours/1349199
• 关键词: Harnessing; Innate; Immune; System; Target

Despite recent improvements in cancer treatments, cancer remains a major cause of death world-wide. This project builds on our recent research demonstrating a novel mechanism by which to 'kick-start' the patient's own immune system to mount an effective anti-cancer response. Specifically we seek to utilise C3aR-targeting antisense oligonucleotides developed by our commercial partner for treatment of advanced cancers that are unresponsive to current immunotherapeutic approaches.

尽管最近癌症治疗方法有所改进，但癌症仍然是全球范围内的主要死亡原因。这个项目建立在我们最近的研究基础上，展示了一种新的机制，通过这种机制可以“启动”患者自己的免疫系统，从而启动有效的抗癌反应。具体地说，我们寻求利用我们的商业合作伙伴开发的C3aR靶向反义寡核苷酸来治疗对当前免疫治疗方法无效的晚期癌症。